Author

C. Zerbe

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Assay:flow cytometry· 1 Research Focus:host-pathogen & immune response· 1 Assay:proteomics· 1

Frequent Co-Authors

A. Fletcher-Etheringon· 1 shared A. Freeman· 1 shared A. J. Davison· 1 shared A. Vargas Hernandez· 1 shared B. L. Strang· 1 shared C. A. Fielding· 1 shared C. Cunningham-Rundles· 1 shared E. C. Y. Wang· 1 shared

Activity by Year

2017-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperMicrobiology

A. Fletcher-Etheringon

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Human cytomegalovirus protein RL1 degrades the antiviral factor SLFN11 via recruitment of the CRL4 E3 ubiquitin ligase complex

K. Nightingale, C. A. Fielding, C. Zerbe, L. Hunter, M. Potts, A. Fletcher-Etheringon, L. Nobre, E. C. Y. Wang, B. L. Strang, J. Houghton, R. Antrobus, N. M. Suarez, J. Nichols, A. J. Davison, R. J. Stanton, M. P. Weekes

This study identifies HCMV protein RL1 as a viral antagonist that degrades SLFN11 via CRL4 E3 ubiquitin ligase, revealing SLFN11's role in restricting HCMV infection.

bioRxiv · May 14, 2021Microbiology

Ruxolitinib partially reverses functional NK cell deficiency in patients with STAT1 gain-of-function mutations

A. Vargas Hernandez, E. M. Mace, O. Zimmerman, C. Zerbe, A. Freeman, S. Rosenzweig, J. W. Leiding, T. Torgerson, M. C. Altman, E. Schussler, C. Cunningham-Rundles, I. K. Chinn, I. C. Hanson, N. L. Rider, S. M. Holland, , L. R. Forbes

This study shows that ruxolitinib partially restores NK cell function in STAT1 GOF patients by reducing STAT1 phosphorylation and improving cytotoxic activity.

bioRxiv · Jun 28, 2017Immunology